Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Nkarta, Inc.NASDAQ: NKTX

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $3.04M fell 33.6% year over year, behind the -21.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +49.6% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.6% toward the trailing-twelve-month pace of -21.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.04M-14.3% QoQ
Last fiscal yearDec 2025
$17.12M-11.8% YoY
LTMMar 2026
$16.38M-21.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.6%——
1 year-11.8%——
3-year CAGR+49.6%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
17.12M USD
Year-over-year change
-11.8%
4-year CAGR
+163.7%

Other Income / Expenses vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.0% is the 3rd highest of 8, against a peer median of -50.1%.
  • Over three fiscal years its annual growth of +49.6% compares with a peer median of -6.7%.
NKTX Competitors
Other Income / Expenses for NKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTXNkarta, Inc.LTM Mar 2026$16.38M USD-21.0%+49.6%—
ALECAlector, Inc.LTM Mar 2026$11.31M USD-50.1%-26.8%61.4%
FATEFate Therapeutics, Inc.LTM Mar 2026$9.52M USD-61.3%-24.7%150.7%
PEPGPepGen Inc.LTM Mar 2026$4.08M USD-37.0%+11.3%—
FBRXForte Biosciences, Inc.LTM Mar 2026$2.53M USD+109.2%+414.8%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$2.61M USD+55.1%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 6.37M CHF-427.8%——
VORVor Biopharma Inc.LTM Mar 2026-$509.57M USD-14437.9%——
Peer median (excluding NKTX) —-50.1%-6.7%106.0%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue005.87M09.19M
Gross Profit00(5.87M)0(9.19M)
Gross Margin—————
Research & Development63.41M90.9M90.9M96.74M90.43M
Selling, General & Admin23.02M28.06M34.88M31.45M31.57M
Operating Expenses86.43M118.96M125.78M128.19M112.01M
Depreciation & Amortization1.76M2.64M5.87M9.15M9.19M
EBITDA(84.32M)(105.61M)(120.48M)(99.64M)(94.89M)
EBITDA Margin—————
Operating Income(86.43M)(118.96M)(131.65M)(128.19M)(121.21M)
Operating Margin—————
Interest Income370K5.59M14.11M19.32M15.49M
Interest Expense05.59M000
Other Income / Expenses354K5.12M14.15M19.4M17.12M
Income Before Tax(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Net Margin—————
EPS (Basic)(2.62)(2.61)(2.40)(1.60)(1.41)
EPS (Diluted)(2.62)(2.61)(2.40)(1.60)(1.41)
Weighted Avg Shares32.86M43.63M49.01M67.87M73.99M
Weighted Avg Shares (Diluted)32.86M43.63M49.01M67.87M73.99M

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.